<p>根据 Altman Advisors Inc.最近向证券交易委员会提交的文件，该公司在第三季度收购了强生（NYSE:JNJ - 免费报告）股票的新头寸。该公司收购了 9,711 股，价值约为 1,574,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>ORIC：与两家制药巨头合作，分析师预计上涨超过 100%</li>
</ul>
<p>其他大型投资者最近也增加或减少了在该公司的股份。Innealta Capital LLC 在第二季度以 27,000 美元的价格购买了强生的新头寸。Highline Wealth Partners LLC 在第三季度以 31,000 美元的价格购买了强生的新头寸。Mowery &amp; Schoenfeld Wealth Management LLC 在第三季度将其在强生的持股增加了 58.7%。Mowery &amp; Schoenfeld Wealth Management LLC 目前拥有 246 股强生股票，价值 40,000 美元，此前在该期间又购买了 91 股。Morton Brown Family Wealth LLC 在第三季度将其在强生的持股增加了 400.0%。Morton Brown Family Wealth LLC 目前拥有 250 股强生股票，价值 41,000 美元，此前在该期间又购买了 200 股。最后，MFA Wealth Advisors LLC 在第二季度以 43,000 美元的价格购买了强生的新头寸。机构投资者持有该公司 69.55% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>多位研究分析师最近对该公司发表了评论。Guggenheim 将强生的目标价从 156.00 美元上调至 162.00 美元，并在 11 月 6 日的研究报告中给予该股票 “中性” 评级。Wells Fargo &amp; Company 将强生的目标价从 163.00 美元上调至 166.00 美元，并在 10 月 16 日的研究报告中给予该股票 “等权重” 评级。StockNews.com 在 9 月 14 日的研究报告中将强生的评级从 “买入” 上调至 “强力买入”。Daiwa America 在 7 月 23 日的研究报告中将强生的评级从 “强力买入” 下调至 “持有”。最后，加拿大皇家银行在 10 月 16 日的研究报告中将强生的目标价从 178.00 美元上调至 181.00 美元，并给予该股票 “跑赢大盘” 评级。七位研究分析师对该股票给予了持有评级，八位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat，强生目前的平均评级为 “适度买入”，共识目标价为 175.94 美元。</p>
<ul>
<li>发现 2024 年表现最佳的三只生物科技 IPO 股票</li>
</ul>
<p><strong>阅读我们对 JNJ 的最新股票分析</strong></p>
<h2>强生股票表现</h2>
<p>强生股票在周三开盘价为 152.30 美元。该公司的 50 日移动平均价格为 160.83 美元，200 日移动平均价格为 156.19 美元。强生的 12 个月低点为 143.13 美元，12 个月高点为 168.85 美元。该公司的市值为 3666.8 亿美元，市盈率为 22.14，PEG 比率为 2.74，贝塔值为 0.53。该公司的流动比率为 1.03，速动比率为 0.79，债务股本比率为 0.45。</p>
<ul>
<li>适合长期投资者的最佳制药股票：增长与分红</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近在 10 月 15 日星期二公布了季度财报。该公司报告季度每股收益为 2.42 美元，超出分析师一致预期的 2.21 美元，超出幅度为 0.21 美元。强生的股本回报率为 35.45%，净利润率为 19.14%。该公司在本季度的收入为 224.7 亿美元，而分析师预期为 221.7 亿美元。去年同期，该公司的每股收益为 2.66 美元。该公司的季度收入同比增长 5.2%。股票研究分析师预测，强生在本年度将发布 9.93 美元的每股收益。</p>
<h2>强生分红公告</h2>
<p>该公司最近还披露了季度分红，将于 12 月 10 日星期二支付。11 月 26 日星期二的股东将获得每股 1.24 美元的分红。除息日为 11 月 26 日星期二。这代表着年化分红为 4.96 美元，分红收益率为 3.26%。强生的分红支付比率（DPR）为 71.78%。</p>
<h2>强生内部交易</h2>
<p>在其他消息中，副总裁 Robert J. Decker 在 8 月 30 日星期五的交易中出售了 5,635 股公司的股票。该股票以 165.06 美元的平均价格出售，总交易额为 930,113.10 美元。交易完成后，该副总裁现在直接拥有该公司 18,973 股股票，价值 3,131,683.38 美元。此交易代表其持股减少了 22.90%。该出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。0.16% 的股票由公司内部人士持有。</p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生及其子公司在全球范围内研究、开发、制造和销售各种医疗保健产品。该公司的创新药物部门提供多种治疗领域的产品，如免疫学，包括类风湿关节炎、银屑病关节炎、炎症性肠病和银屑病；传染病，包括 HIV/AIDS；神经科学，包括情绪障碍、神经退行性疾病和精神分裂症；肿瘤学，包括前列腺癌、血液恶性肿瘤、肺癌和膀胱癌；心血管和代谢，包括血栓、糖尿病和黄斑变性；以及肺动脉高压，通过零售商、批发商、分销商、医院和医疗专业人员进行处方使用。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>复利及其在投资中的重要性</li>
<li>Williams-Sonoma 股票：买入并永不放手</li>
<li>除了喝咖啡，还有三种投资咖啡的方法</li>
<li>5 只值得买入并长期持有的分红 ETF</li>
<li>风险承受能力因人而异</li>
<li>伯克希尔购买了 POOL 股票：是时候下手了吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<p>→ [625,000% 收益] – 你准备好迎接下一个山寨币热潮了吗？（来自加密货币交换利润）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE2Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE2Mg"/></p>
<h2>你现在应该投资$1,000 在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Altman Advisors Inc. 在第三季度新建了对强生（NYSE:JNJ）的持仓，购买了 9,711 股，价值约为 574,000 美元。其他机构投资者也调整了他们在该公司的持股。分析师们提高了对 JNJ 的目标价，普遍评级为 “适度买入”，目标价为 94 美元。强生报告的季度每股收益为 2.42 美元，超出预期，并宣布每股派息 1.24 美元，收益率为 3.26%</p>

<p>Altman Advisors Inc. acquired a new position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 9,711 shares of the company's stock, valued at approximately $1,574,000.</p>
<div class="lb-trans"><p>根据 Altman Advisors Inc.最近向证券交易委员会提交的文件，该公司在第三季度收购了强生（NYSE:JNJ - 免费报告）股票的新头寸。该公司收购了 9,711 股，价值约为 1,574,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>ORIC: Working with Two Pharma Giants, Analysts See +100% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>ORIC：与两家制药巨头合作，分析师预计上涨超过 100%</li>
</ul>
</div><p>Other large investors have also recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in Johnson &amp; Johnson during the 2nd quarter worth $27,000. Highline Wealth Partners LLC bought a new position in Johnson &amp; Johnson during the 3rd quarter worth $31,000. Mowery &amp; Schoenfeld Wealth Management LLC increased its position in Johnson &amp; Johnson by 58.7% during the 3rd quarter. Mowery &amp; Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares during the period. Morton Brown Family Wealth LLC increased its position in shares of Johnson &amp; Johnson by 400.0% in the third quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company's stock worth $41,000 after purchasing an additional 200 shares during the period. Finally, MFA Wealth Advisors LLC bought a new position in shares of Johnson &amp; Johnson in the second quarter worth $43,000. Institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者最近也增加或减少了在该公司的股份。Innealta Capital LLC 在第二季度以 27,000 美元的价格购买了强生的新头寸。Highline Wealth Partners LLC 在第三季度以 31,000 美元的价格购买了强生的新头寸。Mowery &amp; Schoenfeld Wealth Management LLC 在第三季度将其在强生的持股增加了 58.7%。Mowery &amp; Schoenfeld Wealth Management LLC 目前拥有 246 股强生股票，价值 40,000 美元，此前在该期间又购买了 91 股。Morton Brown Family Wealth LLC 在第三季度将其在强生的持股增加了 400.0%。Morton Brown Family Wealth LLC 目前拥有 250 股强生股票，价值 41,000 美元，此前在该期间又购买了 200 股。最后，MFA Wealth Advisors LLC 在第二季度以 43,000 美元的价格购买了强生的新头寸。机构投资者持有该公司 69.55% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research analysts recently commented on the company. Guggenheim raised their price target on Johnson &amp; Johnson from $156.00 to $162.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, November 6th. Wells Fargo &amp; Company raised their price target on Johnson &amp; Johnson from $163.00 to $166.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, October 16th. StockNews.com upgraded Johnson &amp; Johnson from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, September 14th. Daiwa America cut Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, July 23rd. Finally, Royal Bank of Canada raised their price target on Johnson &amp; Johnson from $178.00 to $181.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson &amp; Johnson presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $175.94.</p>
<div class="lb-trans"><p>多位研究分析师最近对该公司发表了评论。Guggenheim 将强生的目标价从 156.00 美元上调至 162.00 美元，并在 11 月 6 日的研究报告中给予该股票 “中性” 评级。Wells Fargo &amp; Company 将强生的目标价从 163.00 美元上调至 166.00 美元，并在 10 月 16 日的研究报告中给予该股票 “等权重” 评级。StockNews.com 在 9 月 14 日的研究报告中将强生的评级从 “买入” 上调至 “强力买入”。Daiwa America 在 7 月 23 日的研究报告中将强生的评级从 “强力买入” 下调至 “持有”。最后，加拿大皇家银行在 10 月 16 日的研究报告中将强生的目标价从 178.00 美元上调至 181.00 美元，并给予该股票 “跑赢大盘” 评级。七位研究分析师对该股票给予了持有评级，八位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat，强生目前的平均评级为 “适度买入”，共识目标价为 175.94 美元。</p>
</div><ul>
<li>Discover the 3 Best-Performing Biotech IPO Stocks of 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>发现 2024 年表现最佳的三只生物科技 IPO 股票</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 JNJ 的最新股票分析</strong></p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>强生股票表现</h2>
</div><p>Shares of JNJ stock opened at $152.30 on Wednesday. The business's 50-day moving average price is $160.83 and its 200-day moving average price is $156.19. Johnson &amp; Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The firm has a market capitalization of $366.68 billion, a price-to-earnings ratio of 22.14, a PEG ratio of 2.74 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.</p>
<div class="lb-trans"><p>强生股票在周三开盘价为 152.30 美元。该公司的 50 日移动平均价格为 160.83 美元，200 日移动平均价格为 156.19 美元。强生的 12 个月低点为 143.13 美元，12 个月高点为 168.85 美元。该公司的市值为 3666.8 亿美元，市盈率为 22.14，PEG 比率为 2.74，贝塔值为 0.53。该公司的流动比率为 1.03，速动比率为 0.79，债务股本比率为 0.45。</p>
</div><ul>
<li>Best Pharma Stocks for Long-Term Investors: Growth and Dividends</li>
</ul>
<div class="lb-trans"><ul>
<li>适合长期投资者的最佳制药股票：增长与分红</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. Johnson &amp; Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the firm posted $2.66 earnings per share. The business's revenue for the quarter was up 5.2% on a year-over-year basis. Equities research analysts forecast that Johnson &amp; Johnson will post 9.93 EPS for the current year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近在 10 月 15 日星期二公布了季度财报。该公司报告季度每股收益为 2.42 美元，超出分析师一致预期的 2.21 美元，超出幅度为 0.21 美元。强生的股本回报率为 35.45%，净利润率为 19.14%。该公司在本季度的收入为 224.7 亿美元，而分析师预期为 221.7 亿美元。去年同期，该公司的每股收益为 2.66 美元。该公司的季度收入同比增长 5.2%。股票研究分析师预测，强生在本年度将发布 9.93 美元的每股收益。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>强生分红公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.26%. Johnson &amp; Johnson's dividend payout ratio (DPR) is 71.78%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 12 月 10 日星期二支付。11 月 26 日星期二的股东将获得每股 1.24 美元的分红。除息日为 11 月 26 日星期二。这代表着年化分红为 4.96 美元，分红收益率为 3.26%。强生的分红支付比率（DPR）为 71.78%。</p>
</div><h2>Insider Transactions at Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>强生内部交易</h2>
</div><p>In other news, VP Robert J. Decker sold 5,635 shares of the firm's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，副总裁 Robert J. Decker 在 8 月 30 日星期五的交易中出售了 5,635 股公司的股票。该股票以 165.06 美元的平均价格出售，总交易额为 930,113.10 美元。交易完成后，该副总裁现在直接拥有该公司 18,973 股股票，价值 3,131,683.38 美元。此交易代表其持股减少了 22.90%。该出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。0.16% 的股票由公司内部人士持有。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.</p>
<div class="lb-trans"><p>强生及其子公司在全球范围内研究、开发、制造和销售各种医疗保健产品。该公司的创新药物部门提供多种治疗领域的产品，如免疫学，包括类风湿关节炎、银屑病关节炎、炎症性肠病和银屑病；传染病，包括 HIV/AIDS；神经科学，包括情绪障碍、神经退行性疾病和精神分裂症；肿瘤学，包括前列腺癌、血液恶性肿瘤、肺癌和膀胱癌；心血管和代谢，包括血栓、糖尿病和黄斑变性；以及肺动脉高压，通过零售商、批发商、分销商、医院和医疗专业人员进行处方使用。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Williams-Sonoma Stock: Buy It and Never Let It Go</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>5 Dividend ETFs to Buy and Hold Forever</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>Berkshire Buys POOL Stock: Is It Time to Take the Plunge?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>复利及其在投资中的重要性</li>
<li>Williams-Sonoma 股票：买入并永不放手</li>
<li>除了喝咖啡，还有三种投资咖啡的方法</li>
<li>5 只值得买入并长期持有的分红 ETF</li>
<li>风险承受能力因人而异</li>
<li>伯克希尔购买了 POOL 股票：是时候下手了吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><p>→ [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (From Crypto Swap Profits)(Ad)</p>
<div class="lb-trans"><p>→ [625,000% 收益] – 你准备好迎接下一个山寨币热潮了吗？（来自加密货币交换利润）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE2Mg" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10162&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Johnson &amp; Johnson right now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Altman Advisors Inc. 在强生公司（纽约证券交易所代码：JNJ）进行了新的 157 万美元投资